<?xml version='1.0' encoding='utf-8'?>
<document id="21339064"><sentence text="A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study."><entity charOffset="39-50" id="DDI-PubMed.21339064.s1.e0" text="cabazitaxel" /><entity charOffset="52-59" id="DDI-PubMed.21339064.s1.e1" text="XRP6258" /><entity charOffset="81-93" id="DDI-PubMed.21339064.s1.e2" text="capecitabine" /><entity charOffset="154-167" id="DDI-PubMed.21339064.s1.e3" text="anthracycline" /><entity charOffset="172-178" id="DDI-PubMed.21339064.s1.e4" text="taxane" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e0" e2="DDI-PubMed.21339064.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e0" e2="DDI-PubMed.21339064.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e0" e2="DDI-PubMed.21339064.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e0" e2="DDI-PubMed.21339064.s1.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e0" e2="DDI-PubMed.21339064.s1.e4" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e1" e2="DDI-PubMed.21339064.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e1" e2="DDI-PubMed.21339064.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e1" e2="DDI-PubMed.21339064.s1.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e1" e2="DDI-PubMed.21339064.s1.e4" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e2" e2="DDI-PubMed.21339064.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e2" e2="DDI-PubMed.21339064.s1.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e2" e2="DDI-PubMed.21339064.s1.e4" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e3" e2="DDI-PubMed.21339064.s1.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s1.e3" e2="DDI-PubMed.21339064.s1.e4" /></sentence><sentence text="Most patients with metastatic breast cancer (MBC) progress after chemotherapy" /><sentence text=" Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines"><entity charOffset="1-12" id="DDI-PubMed.21339064.s3.e0" text="Cabazitaxel" /><entity charOffset="14-21" id="DDI-PubMed.21339064.s3.e1" text="XRP6258" /><entity charOffset="32-38" id="DDI-PubMed.21339064.s3.e2" text="taxoid" /><pair ddi="false" e1="DDI-PubMed.21339064.s3.e0" e2="DDI-PubMed.21339064.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21339064.s3.e0" e2="DDI-PubMed.21339064.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s3.e0" e2="DDI-PubMed.21339064.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s3.e1" e2="DDI-PubMed.21339064.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s3.e1" e2="DDI-PubMed.21339064.s3.e2" /></sentence><sentence text=" The objectives of this phase I/II study were to assess the maximum tolerated dose (MTD), safety profile, pharmacokinetics, and activity of cabazitaxel plus capecitabine in patients with MBC who had been previously treated with taxanes and anthracyclines"><entity charOffset="140-151" id="DDI-PubMed.21339064.s4.e0" text="cabazitaxel" /><entity charOffset="157-169" id="DDI-PubMed.21339064.s4.e1" text="capecitabine" /><entity charOffset="228-235" id="DDI-PubMed.21339064.s4.e2" text="taxanes" /><entity charOffset="240-254" id="DDI-PubMed.21339064.s4.e3" text="anthracyclines" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e0" e2="DDI-PubMed.21339064.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e0" e2="DDI-PubMed.21339064.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e0" e2="DDI-PubMed.21339064.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e0" e2="DDI-PubMed.21339064.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e1" e2="DDI-PubMed.21339064.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e1" e2="DDI-PubMed.21339064.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e1" e2="DDI-PubMed.21339064.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e2" e2="DDI-PubMed.21339064.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s4.e2" e2="DDI-PubMed.21339064.s4.e3" /></sentence><sentence text="" /><sentence text="In part I, we used a 3+3 dose-escalation scheme to assess the MTD of intravenous cabazitaxel (day 1) with oral capecitabine twice daily (days 1-14) every 3 weeks"><entity charOffset="81-92" id="DDI-PubMed.21339064.s6.e0" text="cabazitaxel" /><entity charOffset="111-123" id="DDI-PubMed.21339064.s6.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.21339064.s6.e0" e2="DDI-PubMed.21339064.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21339064.s6.e0" e2="DDI-PubMed.21339064.s6.e1" /></sentence><sentence text=" In part II, we evaluated the objective response rate (ORR) at the MTD" /><sentence text="" /><sentence text="Thirty-three patients were enrolled and treated (15 in part I; 18 in part II)" /><sentence text=" Cabazitaxel 20mg/m(2) plus capecitabine 1000 mg/m(2) was the MTD"><entity charOffset="1-12" id="DDI-PubMed.21339064.s10.e0" text="Cabazitaxel" /><entity charOffset="28-40" id="DDI-PubMed.21339064.s10.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.21339064.s10.e0" e2="DDI-PubMed.21339064.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21339064.s10.e0" e2="DDI-PubMed.21339064.s10.e1" /></sentence><sentence text=" Pharmacokinetic analysis showed no apparent drug-drug interaction" /><sentence text=" In all patients, the main grade 3-4 toxicities were asthenia (n=5), hand-foot syndrome (n=5), neutropenia (n=21), neutropenic infection (n=1), and neutropenic colitis (n=1)" /><sentence text=" One patient had febrile neutropenia" /><sentence text=" Antitumour activity was observed at all dose-levels with two complete responses, five partial responses (PRs), and 20 disease stabilisations (seven unconfirmed PR)" /><sentence text=" At the MTD, 21 patients were evaluable for efficacy" /><sentence text=" The ORR was 23" /><sentence text="8% (95% CI: 8" /><sentence text="2-47" /><sentence text="2%)" /><sentence text=" The median response duration was 3" /><sentence text="1 months (95% CI: 2" /><sentence text="1-8" /><sentence text="4 months), with four of five lasting for more than 3 months" /><sentence text=" Median time to progression was 4" /><sentence text="9 months" /><sentence text="" /><sentence text="Cabazitaxel combined with capecitabine is active, has a safety profile consistent with a taxane plus capecitabine combination and warrants further investigation in patients with MBC"><entity charOffset="0-11" id="DDI-PubMed.21339064.s27.e0" text="Cabazitaxel" /><entity charOffset="26-38" id="DDI-PubMed.21339064.s27.e1" text="capecitabine" /><entity charOffset="89-95" id="DDI-PubMed.21339064.s27.e2" text="taxane" /><entity charOffset="101-113" id="DDI-PubMed.21339064.s27.e3" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e0" e2="DDI-PubMed.21339064.s27.e0" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e0" e2="DDI-PubMed.21339064.s27.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e0" e2="DDI-PubMed.21339064.s27.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e0" e2="DDI-PubMed.21339064.s27.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e1" e2="DDI-PubMed.21339064.s27.e1" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e1" e2="DDI-PubMed.21339064.s27.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e1" e2="DDI-PubMed.21339064.s27.e3" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e2" e2="DDI-PubMed.21339064.s27.e2" /><pair ddi="false" e1="DDI-PubMed.21339064.s27.e2" e2="DDI-PubMed.21339064.s27.e3" /></sentence><sentence text="" /></document>